{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-273317","form_type":"8-K","ticker":"QDEL","cik":"0001906324","company_name":"QuidelOrtho Corp","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.041756+00:00","generated_at":"2026-05-16T22:40:49.985637+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"QuidelOrtho Q3: revenue $700M, adj. EBITDA margin 25%, core growth 5% YoY","bullets":["Total revenue $700M; core revenue (ex-COVID/Donor Screening) grew 5% as reported.","Adjusted EBITDA margin improved 180 bps to 25%; full-year guidance maintained at 22%.","Labs +4%, IH +5%, Triage +7% (constant currency); non-respiratory up 6% CC.","Respiratory revenue $112M (-32% YoY); COVID sales down 63%.","Pending LEX Diagnostics acquisition on track; VITROS High Sensitivity Troponin cleared in U.S."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-273317","json":"https://secwatch.observer/filing/0001193125-25-273317.json","markdown":"https://secwatch.observer/filing/0001193125-25-273317.md","text":"https://secwatch.observer/filing/0001193125-25-273317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1906324/000119312525273317/0001193125-25-273317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1906324/000119312525273317/d79385d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:40:49.985637+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}